达格列净延长HFrEF患者无事件生存与总生存的探索性分析
该研究基于DAPA-HF随机对照试验的探索性分析,将达格列净10mg每日一次与安慰剂对比,并将试验结果外推至患者终生,以估算长期治疗效应。
要点
- 达格列净使65岁HFrEF患者主要复合终点无事件生存时间增加2.1年。
- 达格列净使65岁HFrEF患者总生存时间增加1.7年。
- 在各年龄亚组中达格列净对无事件生存和总生存的获益一致。
核心结论
- 达格列净在HFrEF患者中提供具有临床意义的无事件生存和总生存外推获益。
研究设计与样本
- DAPA-HF为3期随机安慰剂对照试验,在20个国家410个中心纳入4744例HFrEF患者。
- 患者射血分数≤40%,NYHA II-IV级,NT-proBNP升高,平均随访17.6(标准差5.2)个月。
- 干预为达格列净10mg每日一次对比安慰剂,均加标准治疗。
主要发现
- 在DAPA-HF各亚组分析中,达格列净对无事件生存和总生存的获益一致。
临床怎么用
- 可将终生外推的无事件生存和总生存获益用于与HFrEF患者沟通达格列净的治疗价值。
局限性
- 该分析为探索性分析,结果基于试验数据的外推估算,非直接长期随访观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sodium glucose cotransporter 2 inhibitors reduce morbidity and mortality in patients with heart failure and reduced ejection fraction (HFrEF). Clinicians may find estimates of the projected long-term benefits of sodium glucose cotransporter 2 inhibitors a helpful addition to clinical trial results when communicating the benefits of this class of drug to patients. OBJECTIVE: To estimate the projected long-term treatment effects of dapagliflozin in patients with HFrEF over the duration of a patient's lifetime. DESIGN, SETTING, AND PARTICIPANTS: Exploratory analysis was performed of Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF), a phase 3 randomized, placebo-controlled clinical trial conducted at 410 sites in 20 countries. Patients with an ejection fraction less than or equal to 40% in New York Heart Association functional classification II to IV and elevated plasma levels of N-terminal pro B-type natriuretic peptide were enrolled between February 15, 2017, and August 17, 2018, with final follow-up on June 6, 2019. Mean (SD) duration of follow-up was 17.6 (5.2) months. INTERVENTIONS: Dapagliflozin, 10 mg, once daily vs placebo in addition to standard therapy. MAIN OUTCOMES AND MEASURES: The primary composite outcome was time to first hospitalization for heart failure, urgent heart failure visit requiring intravenous therapy, or cardiovascular death. The trial results were extrapolated to estimate the projected long-term treatment effects of dapagliflozin over the duration of a patient's lifetime for the primary outcome and the secondary outcome of death from any cause. RESULTS: A total of 4744 patients (1109 women [23.4%]; 3635 men [76.6%]) were randomized in DAPA-HF, with a mean (SD) age of 66.3 (10.9) years. The extrapolated mean event-free survival for an individual aged 65 years from a primary composite end point event was 6.2 years for placebo and 8.3 years for dapagliflozin, representing an event-free survival time gain of 2.1 years (95% CI, 0.8-3.3 years; P = .002). When considering death from any cause, mean extrapolated life expectancy for an individual aged 65 years was 9.1 years for placebo and 10.8 years for dapagliflozin, with a gain in survival of 1.7 years (95% CI, 0.1-3.3; P = .03) with dapagliflozin. Similar results were seen when extrapolated across the age range studied. In analyses of subgroups of patients in DAPA-HF, consistent benefits were seen with dapagliflozin on both event-free and overall survival. CONCLUSIONS AND RELEVANCE: These findings indicate that dapagliflozin provides clinically meaningful gains in extrapolated event-free and overall survival. These findings may be helpful in communicating the benefits of this treatment to patients with HFrEF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03036124.
引用
- Docherty KF, Jhund PS, Claggett B, et al. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. JAMA Cardiol. 2021. PMID: 34319398. doi:10.1001/jamacardio.2021.2632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。